Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®

References

• U.S. Food and Drug Administration. FDA is a biological product? [accessed 2016 Dec 21] http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194516.html
   Google Scholar
• Jung SK, Lee KH, Jeon JW, Lee JW, Kwon BO, Kim YJ, Bae JS, Kim DI, Lee SY, Chang SJ. Physicochemical characterization of Remsima. mAbs 2014;61163-1173; PMID:25517302; http://dx.doi.org/10.4161/mabs.32221
   PubMed Web of Science ®Google Scholar
• Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim HK, Heinonem E, Ho K, et al. Biosimilars: what clinicians should know. Blood 2012;120:5111-5117; PMID:23093622; http://dx.doi.org/10.1182/blood-2012-04-425744
   PubMed Web of Science ®Google Scholar
• Cornes P. The economic pressures for biosimilar drug use in cancer medicine. Target Oncol 2012; 7:S57-S67; PMID: 22249658; http://dx.doi.org/10.1007/s11523-011-0196-3
   PubMed Web of Science ®Google Scholar
• McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs 2011;3:209-217; PMID:21441787; http://dx.doi.org/10.4161/mabs.3.2.15005
   PubMed Web of Science ®Google Scholar
• Jha A, Upton A, Dunlop WC, Akehurst R. The budget impact of biosimilar infliximab (Remsima®) for the treatment of autoimmune diseases in five European countries. Adv Ther 2015;32:742-756; PMID:26343027; http://dx.doi.org/10.1007/s12325-015-0233-1
   PubMed Web of Science ®Google Scholar
• Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood 2014;124:3191-3196; PMID:25298038; http://dx.doi.org/10.1182/blood-2014-06-583617
   PubMed Web of Science ®Google Scholar
• AbbVie Inc. HUMIRA (adalimumab) injection, for subcutaneous use. 2016 Oct. [accessed 2016 Dec 21] http://www.rxabbvie.com/pdf/humira.pdf
   Google Scholar
• AbbVie Inc. SPC Humira 40 mg/0.4 ml Pre-filled Syringe and Pre-filled Pen. 2016 Sep 23. [accessed 2016 Dec 21] https://www.medicines.org.uk/emc/medicine/21201
   Google Scholar
• EMA. Summary of opinion (post authorisation): Humira (adalimumab). 2016 May 26. [accessed 2016 Dec 21] http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000481/WC500207152.pdf
   Google Scholar
• Wen D, Vecchi MM, Gu S, Su L, Dolnikova J, Huang YM, Foley SF, Garber E, Pederson N, Meier W. Discovery and investigation of misincorporation of serine at asparagine positions in recombinant proteins expressed in Chinese hamster ovary cells. J Biol Chem 2009;284:32686-32694; PMID:19783658; http://dx.doi.org/10.1074/jbc.M109.059360
   PubMed Web of Science ®Google Scholar
• Ionescu RM, Vlasak J, Price C, Kirchmeier M. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci 2008;97:1414-1426; PMID:17721938; http://dx.doi.org/10.1002/jps.21104
   PubMed Web of Science ®Google Scholar
• Garber E, Demarest SJ. A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun 2007;355:751-757; PMID:17321501; http://dx.doi.org/10.1016/j.bbrc.2007.02.042
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. Guidance for Industry. [accessed 2016 Dec 21] http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf
   Google Scholar
• Brorson K, Kendrick B. Perspectives on well-characterized biological proteins. In: Schiel JE, Davis Dl, Borisov OV, editors. State-of-the-art and emerging technologies for therapeutic monoclonal antibody characterization. Vol. 1. Monoclonal anti-body therapeutics: structure, function, and regulatory space. Washington, DC: ACS; 2014. p. 99-116; doi:10.1021/bk-2014-1176.ch004
   Google Scholar
• Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29:310-312; PMID:21478841; http://dx.doi.org/10.1038/nbt.1839
   PubMed Web of Science ®Google Scholar
• Wang W, Vlasak J, Li Y, Pristatsky P, Fang Y, Pittman T, Roman J, Wang Y, Preksaritanont T, Ionescu R. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol 2011;48:860-866; PMID:21256596; http://dx.doi.org/10.1016/j.molimm.2010.12.009
   PubMed Web of Science ®Google Scholar
• Bertolotti-Ciarlet A, Wang W, Lownesa R, Pristatskya P, Fang Y, McKelvey T, Li Y, Li Y, Drummond J, Prueksarita T, et al. Impact of methionine oxidation on the binding of human IgG1 to FcRn and Fcγ receptors. Mol Immunol 2009;46:1878-1882; PMID:19269032; http://dx.doi.org/10.1016/j.molimm.2009.02.002
   PubMed Web of Science ®Google Scholar
• Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281(33):23514-23524. Epub 2006 Jun 21; PMID:16793771; http://dx.doi.org/10.1074/jbc.M604292200
   PubMed Web of Science ®Google Scholar
• Robbie GJ, Criste R, Dall'acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 2013; 57(12):6147-6153; PMID:24080653; http://dx.doi.org/10.1128/AAC.01285-13
   PubMed Web of Science ®Google Scholar
• Hyland E, Mant T, Vlachos P, Attkins N, Ullmann M, Roy S, Wagner V. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira® in healthy subjects. Br J Clin Pharmacol 2016;82:983-993; PMID:27285856; http://dx.doi.org/10.1111/bcp.13039
   PubMed Web of Science ®Google Scholar
• Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C, Schiestl M. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs 2013; 27(5):495-507; PMID:23649935; http://dx.doi.org/10.1007/s40259-013-0036-3
   PubMed Web of Science ®Google Scholar
• Tebbey PW, Varga A, Naill M, Clewell J, Venema J. Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab). mAbs 2015;7(5):805-811; PMID:26230301; http://dx.doi.org/10.1080/19420862.2015.1073429
   PubMed Web of Science ®Google Scholar
• Terlizzese M, Simoni P, Antonetti F. In vitro comparison of inhibiting ability of soluble TNF receptor p75 (TBP II) vs. soluble TNF receptor p55 (TBP I) against TNF-alpha and TNF-beta. J Interferon Cytokine Res 1996; 16:1047-1053; PMID: 8974008; https://dx.doi.org/10.1089/jir.1996.16.1047
   PubMed Web of Science ®Google Scholar
• Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, Salfield J, Sasso EH. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009; 131:308-316; PMID:19188093; http://dx.doi.org/10.1016/j.clim.2009.01.002
   PubMed Web of Science ®Google Scholar
• Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T. Differences in binding and effector functions between classes of TNF antagonists. Cytokine 2009; 45:124-31; PMID:19128982; http://dx.doi.org/10.1016/j.cyto.2008.11.008
   PubMed Web of Science ®Google Scholar
• Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83:793-802; PMID:8521496; http://dx.doi.org/10.1016/0092-8674(95)90192-2
   PubMed Web of Science ®Google Scholar
• ICH harmonised tripartite guideline. Validation of analytical procedures: text and methodology Q2(R1). Current Step 4 version. 2005 Nov. [accessed 2016 Dec 21] http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf
   Google Scholar